Beta Bionics (BBNX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 21, 2026, will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders will vote on electing two Class I directors and ratifying Ernst & Young LLP as the independent auditor for 2026.

• Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.

• Forward-looking statements address executive compensation and business strategy, subject to risks and uncertainties.

Voting matters and shareholder proposals

• Two Class I directors, Sean Carney and Christy Jones, are nominated for election to serve until 2029.

• Proposal to ratify Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Shareholders may submit proposals or director nominations for the 2027 Annual Meeting, following specific deadlines and requirements.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with staggered three-year terms.

• Majority of directors are independent per Nasdaq standards; board leadership is separated between an independent Chair and CEO.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.

• Directors are expected to attend all meetings; no director attended fewer than 75% of meetings in 2025.

• Code of Business Conduct and Ethics and Insider Trading Policy are in place for all directors and employees.